Loading…
← CockpitCompetitor Analysis › 002412.SZ Hunan Hansen Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hunan Hansen Pharmaceutical Co., Ltd. Class A002412.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum leader 82
Mkt cap
$532M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$24.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+2.6 pp
WACC 7.0%
Hurdle
-6 pp
Req g minus delivered
Close · CNYCN¥7.10
1D-1.4%
1W-11.0%
1M-11.7%
3M-3.3%
6M-1.8%
YTD+10.8%
1Y+8.9%
ATR %4.9%
52w lowhigh50.1% off high

What Hunan Hansen Pharmaceutical does

Employees: 2,108

Hunan Hansen Pharmaceutical at a glance

Size Hunan Hansen Pharmaceutical (002412.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $532M, the 3549th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.10 on 18 Nov 2026.

Performance Over six months the shares fell 1.8%, against -22.9% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue fell 4.2% over the last twelve months (peer median -0.7%); the operating margin is 20.9% (peer median 8.5%).

Valuation It trades at 3.0× enterprise value to sales against a peer median of 2.9× (9th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.6 points above its cost of capital (7.0% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026002412.SZ 100Peer median 77
Six months, rebased to 100: Hunan Hansen Pharmaceutical against the median of its 20 peers (local-currency closes).

Hunan Hansen Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.01BCN¥1.03BCN¥993MCN¥944MCN¥905M
Revenue growth—+3%+5%+4%—
Gross profitCN¥808MCN¥777MCN¥736MCN¥671MCN¥633M
EBITDAn/aCN¥270MCN¥278MCN¥222MCN¥186M
Net incomeCN¥272MCN¥198MCN¥220MCN¥205MCN¥168M
Free cash flowCN¥214MCN¥237MCN¥135MCN¥159MCN¥133M
Capital expenditureCN¥11.0MCN¥11.1MCN¥11.6MCN¥19.5MCN¥11.5M
Total debtCN¥2.41MCN¥72.6MCN¥96.6MCN¥109MCN¥139M

Quarterly statements and history in the cockpit →

Hunan Hansen Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%002644AVBP30150730026160366931745007753001580025623000396004883007912877BOI6032620460300519002412.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hunan Hansen Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2.5×5×7.5×0026443015073002616036693174500775300158002562002826300039600488300791BOI17076032620460300519002412.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hunan Hansen Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%-10%0%+10%+20%-20%0%20%002644301507002562002826300039600488300791BOI1707603262002412.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hunan Hansen Pharmaceutical is the large dot.

Hunan Hansen Pharmaceutical competitors and peer comparison

How Hunan Hansen Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hunan Hansen Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002412.SZPeer medianRank in peer set
1-month return-11.7%-10.3%8th lowest of 21
6-month return-1.8%-22.9%2nd highest of 21
Distance from 52-week high-50.1%-44.4%7th lowest of 21
Revenue growth (TTM)-4.2%-0.7%9th lowest of 19
Operating margin20.9%8.5%5th highest of 21
EV / Sales3.0×2.9×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)1.4%2.6%6th least demanding of 13
Growth delivered (Del g)+7.0%+4.8%5th highest of 12
Hurdle (Req g minus delivered)-5.5 pp-0.3 pp3rd least demanding of 12
ROIC minus cost of capital+2.6 pp-0.2 pp8th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Boiron BOI.PAFrance$367M-31%-2%5%0.6×-0.8%-0.5%
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%3.0×-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%1.0×-17.2%+2.3%
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
Zhejiang Xinguang Pharmaceutical 300519.SZChina$319M-15%+5%27%5.1×3.1%-1.3%

Questions

Which companies are Hunan Hansen Pharmaceutical's closest peers?
The cockpit's peer set: Lanzhou Foci Pharmaceutical (002644.SZ), ArriVent BioPharma (AVBP), Hangzhou Minsheng Healthcare (301507.SZ), ABA Chemicals (300261.SZ), Lionco Pharmaceutical (603669.SS), Myung in Pharm (317450.KS), CK Life Sciences International (Holdings) (0775.HK), Shanxi Zhendong Pharmaceutical (300158.SZ).
Is Hunan Hansen Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.0× against a peer median of 2.9×, 9th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Hunan Hansen Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -1.8% against -22.9% for the median peer; over one year +8.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.